Nathan P Wiederhold

List of Publications by Year
in descending order

263	11,096	30070 54	46799 89
papers	citations	h-index	g-index

273	273	273	9640
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
2	Antifungal resistance: current trends and future strategies to combat. Infection and Drug Resistance, 2017, Volume 10, 249-259.	2.7	305
3	Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2005, 49, 3624-3630.	3.2	198
4	Fungal Planet description sheets: 469-557. Persoonia: Molecular Phylogeny and Evolution of Fungi, 2016, 37, 218-403.	4.4	196
5	Pharmacodynamics of Caspofungin in a Murine Model of Invasive Pulmonary Aspergillosis: Evidence of Concentrationâ€Dependent Activity. Journal of Infectious Diseases, 2004, 190, 1464-1471.	4.0	195
6	Fungal Planet description sheets: 400â€“468. Persoonia: Molecular Phylogeny and Evolution of Fungi, 2016, 36, 316-458.	4.4	193
7	F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12809-12814.	7.1	187
8	Detection of Gliotoxin in Experimental and Human Aspergillosis. Infection and Immunity, 2005, 73, 635-637.	2.2	171
9	The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs, 2021, 81, 1703-1729.	10.9	168
10	Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection. Antimicrobial Agents and Chemotherapy, 2008, 52, 3783-3785.	3.2	150
11	First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations in Aspergillus fumigatus Isolates in the United States. Journal of Clinical Microbiology, 2016, 54, 168-171.	3.9	143
12	Fungal infections in animals: a patchwork of different situations. Medical Mycology, 2018, 56, S165-S187.	0.7	141
13	The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opinion on Investigational Drugs, 2003, 12, 1313-1333.	4.1	130
14	Coelomycetous Dothideomycetes with emphasis on the families Cucurbitariaceae and Didymellaceae. Studies in Mycology, 2018, 90, 1-69.	7.2	129
15	Attenuation of the Activity of Caspofungin at High Concentrations against Candida albicans : Possible Role of Cell Wall Integrity and Calcineurin Pathways. Antimicrobial Agents and Chemotherapy, 2005, 49, 5146-5148.	3.2	127
16	Fungal Planet description sheets: 558â€“624. Persoonia: Molecular Phylogeny and Evolution of Fungi, 2017, 38, 240-384.	4.4	126
17	Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids. MBio, 2015, 6, e00647.	4.1	124
18	Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole. Mycopathologia, 2010, 170, 291-313.	3.1	118

#	Article	IF	Citations
19	Antifungal Susceptibilities among Different Serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 2009, 53, 309-311.	3.2	114
20	International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 2016, 60, 1079-1084.	3.2	113
21	In Vitro Pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole againstAspergillus,Fusarium, andScedosporiumspp. Antimicrobial Agents and Chemotherapy, 2005, 49, 945-951.	3.2	111
22	The antifungal arsenal: alternative drugs and future targets. International Journal of Antimicrobial Agents, 2018, 51, 333-339.	2.5	110
23	Cladosporium Species Recovered from Clinical Samples in the United States. Journal of Clinical Microbiology, 2015, 53, 2990-3000.	3.9	109
24	Phylogenomic Analysis of a 55.1-kb 19-Gene Dataset Resolves a MonophyleticFusariumthat Includes theFusarium solaniSpecies Complex. Phytopathology, 2021, 111, 1064-1079.	2.2	107
25	Molecular diagnostics in medical mycology. Nature Communications, 2018, 9, 5135.	12.8	103
26	Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. Journal of Antimicrobial Chemotherapy, 2004, 54, 376-385.	3.0	100
27	Frequency and Species Distribution of Gliotoxin-Producing Aspergillus Isolates Recovered from Patients at a Tertiary-Care Cancer Center. Journal of Clinical Microbiology, 2005, 43, 6120-6122.	3.9	99
28	New species of <I>Cladosporium</I> associated with human and animal infections. Persoonia: Molecular Phylogeny and Evolution of Fungi, 2016, 36, 281-298.	4.4	95
29	Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokineticâ€“pharmacodynamic models with Monte Carlo simulation. Journal of Antimicrobial Chemotherapy, 2008, 61, 621-628.	3.0	94
30	Pharmacodynamic Activity of Amphotericin B Deoxycholate Is Associated with Peak Plasma Concentrations in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2006, 50, 469-473.	3.2	92
31	Rapid Emergence of Echinocandin Resistance in Candida glabrata Resulting in Clinical and Microbiologic Failure. Antimicrobial Agents and Chemotherapy, 2013, 57, 4559-4561.	3.2	92
32	Mutations in hmg1 , Challenging the Paradigm of Clinical Triazole Resistance in Aspergillus fumigatus. MBio, 2019, 10, .	4.1	85
33	Tollâ€DeficientDrosophilaFlies as a Fast, Highâ€Throughput Model for the Study of Antifungal Drug Efficacy against Invasive Aspergillosis andAspergillusVirulence. Journal of Infectious Diseases, 2005, 191, 1188-1195.	4.0	84
34	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infectious Diseases, The, 2021, 21, e375-e386.	9.1	80
35	Genomewide Expression Profile Analysis of the Candida glabrata Pdr1 Regulon. Eukaryotic Cell, 2011, 10, 373-383.	3.4	77
36	Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi. Virulence, 2017, 8, 138-142.	4.4	75

#	Article	IF	Citations
37	In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera. Antimicrobial Agents and Chemotherapy, 2007, 51, 1616-1620.	3.2	74
38	Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species. Journal of Clinical Microbiology, 2014, 52, 994-997.	3.9	73
39	Multicenter Evaluation of the Vitek MS v3.0 System for the Identification of Filamentous Fungi. Journal of Clinical Microbiology, 2018, 56, .	3.9	73
40	Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans. Journal of Antimicrobial Chemotherapy, 2017, 72, 1977-1980.	3.0	72
41	Review of the Novel Investigational Antifungal Olorofim. Journal of Fungi (Basel, Switzerland), 2020, 6, 122.	3.5	72
42	Phylogeny of the Clinically Relevant Species of the Emerging Fungus Trichoderma and Their Antifungal Susceptibilities. Journal of Clinical Microbiology, 2014, 52, 2112-2125.	3.9	71
43	Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candida auris Candidemia Secondary to Chronic Candiduria. Open Forum Infectious Diseases, 2019, 6, ofz262.	0.9	71
44	The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 7115-7127.	3.2	69
45	Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	68
46	Blastomyces helicus, a New Dimorphic Fungus Causing Fatal Pulmonary and Systemic Disease in Humans and Animals in Western Canada and the United States. Clinical Infectious Diseases, 2019, 68, 188-195.	5.8	68
47	The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy. AIDS Research and Treatment, 2012, 2012, 1-5.	0.7	67
48	Effect of Amphotericin B and Micafungin Combination on Survival, Histopathology, and Fungal Burden in Experimental Aspergillosis in the p47 ^{phox} ^{â^'} [/] ^{â^'} Mouse Model of Chronic Granulomatous Disease. Antimicrobial Agents and Chemotherapy, 2006, 50, 422-427.	3.2	66
49	Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect. Current Opinion in Infectious Diseases, 2007, 20, 574-578.	3.1	63
50	Increases in SLT2 Expression and Chitin Content Are Associated with Incomplete Killing of Candida glabrata by Caspofungin. Antimicrobial Agents and Chemotherapy, 2008, 52, 1144-1146.	3.2	62
51	A Reference Laboratory Experience of Clinically Achievable Voriconazole, Posaconazole, and Itraconazole Concentrations within the Bloodstream and Cerebral Spinal Fluid. Antimicrobial Agents and Chemotherapy, 2014, 58, 424-431.	3.2	61
52	No to Neocosmospora : Phylogenomic and Practical Reasons for Continued Inclusion of the Fusarium solani Species Complex in the Genus Fusarium. MSphere, 2020, 5, .	2.9	61
53	Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species. Journal of Antimicrobial Chemotherapy, 2018, 73, 3063-3067.	3.0	59
54	In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. Journal of Antimicrobial Chemotherapy, 2009, 64, 79-83.	3.0	58

#	Article	IF	Citations
55	Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 600-608.	4.3	58
56	The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrobial Agents and Chemotherapy, 2016, 60, 2528-2531.	3.2	58
57	Drug delivery strategies for improved azole antifungal action. Expert Opinion on Drug Delivery, 2008, 5, 1199-1216.	5.0	57
58	Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans. Antimicrobial Agents and Chemotherapy, 2011, 55, 3254-3260.	3.2	55
59	Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	55
60	The genome of opportunistic fungal pathogen Fusarium oxysporum carries a unique set of lineage-specific chromosomes. Communications Biology, 2020, 3, 50.	4.4	55
61	Efficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 3340-3347.	3.2	54
62	Interlaboratory and Interstudy Reproducibility of a Novel Lateral-Flow Device and Influence of Antifungal Therapy on Detection of Invasive Pulmonary Aspergillosis. Journal of Clinical Microbiology, 2013, 51, 459-465.	3.9	54
63	Coelomycetous Fungi in the Clinical Setting: Morphological Convergence and Cryptic Diversity. Journal of Clinical Microbiology, 2017, 55, 552-567.	3.9	54
64	Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	54
65	Aspergillus fumigatus and pan-azole resistance: who should be concerned?. Current Opinion in Infectious Diseases, 2020, 33, 290-297.	3.1	54
66	The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opinion on Pharmacotherapy, 2007, 8, 1155-1166.	1.8	53
67	The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	53
68	The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans. Antimicrobial Agents and Chemotherapy, 2015, 59, 690-692.	3.2	51
69	Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 199-205.	4.3	50
70	Occurrence of Ochroconis and Verruconis Species in Clinical Specimens from the United States. Journal of Clinical Microbiology, 2014, 52, 4189-4201.	3.9	50
71	Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	50
72	Invasive Aspergillosis in Patients with Hematologic Malignancies. Pharmacotherapy, 2003, 23, 1592-1610.	2.6	49

#	Article	IF	Citations
73	Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans. Antimicrobial Agents and Chemotherapy, 2008, 52, 4145-4148.	3.2	49
74	Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus. Journal of Antimicrobial Chemotherapy, 2018, 73, 404-408.	3.0	49
75	Comparison of Lateral Flow Technology and Galactomannan and (1â†'3)-Î²- <scp>d</scp> -Glucan Assays for Detection of Invasive Pulmonary Aspergillosis. Vaccine Journal, 2009, 16, 1844-1846.	3.1	48
76	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clinical Infectious Diseases, 2021, 72, 1755-1763.	5.8	48
77	Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of Gram-positive catheter-related bacteraemia. Journal of Antimicrobial Chemotherapy, 2005, 55, 792-795.	3.0	47
78	Identification and Antifungal Susceptibility of Penicillium-Like Fungi from Clinical Samples in the United States. Journal of Clinical Microbiology, 2016, 54, 2155-2161.	3.9	47
79	The Solubility Ceiling: A Rationale for Continuous Infusion Amphotericin B Therapy?. Clinical Infectious Diseases, 2003, 37, 871-872.	5.8	46
80	Detection of triazole resistance amongCandidaspecies by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Medical Mycology, 2015, 53, 736-742.	0.7	46
81	Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models. Antimicrobial Agents and Chemotherapy, 2015, 59, 7249-7254.	3.2	46
82	The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	46
83	Emergomyces canadensis,a Dimorphic Fungus Causing Fatal Systemic Human Disease in North America. Emerging Infectious Diseases, 2018, 24, 758-761.	4.3	46
84	In Vivo Efficacy of Aerosolized Nanostructured ItraconazoleFormulations for Prevention of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2006, 50, 1552-1554.	3.2	45
85	Paradoxical echinocandin activity: a limitedin vitrophenomenon?. Medical Mycology, 2009, 47, S369-S375.	0.7	45
86	Disruption of the Transcriptional Regulator Cas5 Results in Enhanced Killing of Candida albicans by Fluconazole. Antimicrobial Agents and Chemotherapy, 2014, 58, 6807-6818.	3.2	45
87	Emergence of Azole Resistance in Aspergillus. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 673-680.	2.1	45
88	In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. European Journal of Pharmaceutical Sciences, 2010, 39, 336-347.	4.0	44
89	VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection. Antimicrobial Agents and Chemotherapy, 2015, 59, 7815-7817.	3.2	44
90	Phylogeny and taxonomic revision of Microascaceae with emphasis on synnematous fungi. Studies in Mycology, 2016, 83, 193-233.	7.2	44

#	Article	IF	Citations
91	In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	43
92	Large-Scale Evaluation of In Vitro Amphotericin B, Triazole, and Echinocandin Activity against Coccidioides Species from U.S. Institutions. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	42
93	Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	42
94	In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin Susceptibility. Antimicrobial Agents and Chemotherapy, 2006, 50, 3926-3928.	3.2	41
95	Inhaled Voriconazole for Prevention of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2009, 53, 2613-2615.	3.2	41
96	Veterinary Fusarioses within the United States. Journal of Clinical Microbiology, 2016, 54, 2813-2819.	3.9	41
97	Culture-Independent Molecular Methods for Detection of Antifungal Resistance Mechanisms and Fungal Identification. Journal of Infectious Diseases, 2017, 216, S458-S465.	4.0	40
98	Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata. Journal of Antimicrobial Chemotherapy, 2018, 73, 448-451.	3.0	40
99	Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis. Journal of Antimicrobial Chemotherapy, 2017, 72, 462-466.	3.0	37
100	Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. Journal of Infection, 2007, 55, 68-74.	3.3	36
101	Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2016, 60, 5600-5603.	3.2	36
102	Combat-Related Pythium aphanidermatum Invasive Wound Infection: Case Report and Discussion of Utility of Molecular Diagnostics. Journal of Clinical Microbiology, 2015, 53, 1968-1975.	3.9	35
103	Antifungal activity againstScedosporiumspecies and novel assays to assess antifungal pharmacodynamics against filamentous fungi. Medical Mycology, 2009, 47, 422-432.	0.7	34
104	The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	34
105	Recommended Education for Pharmacists as Competitive Clinical Scientists. Pharmacotherapy, 2009, 29, 236-244.	2.6	33
106	Limited Activity of Miltefosine in Murine Models of Cryptococcal Meningoencephalitis and Disseminated Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 745-750.	3.2	33
107	The novel arylamidine T-2307 demonstratesin vitroandin vivoactivity against echinocandin-resistantCandida glabrata. Journal of Antimicrobial Chemotherapy, 2016, 71, 692-695.	3.0	33
108	Luliconazole Demonstrates Potent In Vitro Activity against Dermatophytes Recovered from Patients with Onychomycosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 3553-3555.	3.2	32

#	Article	IF	Citations
109	The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	32
110	Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States. Journal of Clinical Microbiology, 2021, 59, e0123021.	3.9	32
111	Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	31
112	Evaluation of Etest Method for Determining Isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 2008, 52, 2959-2961.	3.2	30
113	Echinocandin Resistance in Candida Species: a Review of Recent Developments. Current Infectious Disease Reports, 2016, 18, 42.	3.0	30
114	Dynamics of Mixedâ€“Candida Species Biofilms in Response to Antifungals. Journal of Dental Research, 2018, 97, 91-98.	5.2	30
115	Shielding the Next Generation: Symbiotic Bacteria from a Reproductive Organ Protect Bobtail Squid Eggs from Fungal Fouling. MBio, 2019, 10, .	4.1	30
116	The Novel Arylamidine T-2307 Maintains In Vitro and In Vivo Activity against Echinocandin-Resistant Candida albicans. Antimicrobial Agents and Chemotherapy, 2015, 59, 1341-1343.	3.2	29
117	In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	29
118	Detection and Measurement of Fungal Burden in a Guinea Pig Model of Invasive Pulmonary Aspergillosis by Novel Quantitative Nested Real-Time PCR Compared with Galactomannan and (1,3)-Á-D-Glucan Detection. Journal of Clinical Microbiology, 2012, 50, 602-608.	3.9	28
119	Fatal disseminated Rasamsonia infection in cystic fibrosis post-lung transplantation. Journal of Cystic Fibrosis, 2017, 16, e3-e7.	0.7	28
120	Emerging Fungal Infections: New Species, New Names, and Antifungal Resistance. Clinical Chemistry, 2021, 68, 83-90.	3.2	28
121	Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. International Journal of Pharmaceutics, 2007, 338, 219-224.	5.2	27
122	Species diversity of Aspergillus section Versicolores in clinical samples and antifungal susceptibility. Fungal Biology, 2016, 120, 1458-1467.	2.5	27
123	Four new species of Talaromyces from clinical sources. Mycoses, 2017, 60, 651-662.	4.0	27
124	Ibrexafungerp Demonstrates In Vitro Activity against Fluconazole-Resistant Candida auris and In Vivo Efficacy with Delayed Initiation of Therapy in an Experimental Model of Invasive Candidiasis. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	27
125	Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. Journal of Antimicrobial Chemotherapy, 2008, 62, 1094-1100.	3.0	26
126	Update from the Laboratory. Infectious Disease Clinics of North America, 2016, 30, 13-35.	5.1	26

#	Article	IF	Citations
127	Reduced Antifungal Susceptibility of Vulvovaginal Candida Species at Normal Vaginal pH Levels: Clinical Implications. Journal of Lower Genital Tract Disease, 2018, 22, 152-158.	1.9	26
128	Antifungal Susceptibility Testing: A Primer for Clinicians. Open Forum Infectious Diseases, 2021, 8, ofab444.	0.9	26
129	A murine model of Cryptococcus gattii meningoencephalitis. Journal of Antimicrobial Chemotherapy, 2012, 67, 1432-1438.	3.0	25
130	Murine Model of Invasive Aspergillosis. , 2005, 118, 129-142.		24
131	Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections. Clinical Pharmacology: Advances and Applications, 2016, 8, 1.	1.2	24
132	Efficacy of Posaconazole as Treatment and Prophylaxis against Fusarium solani. Antimicrobial Agents and Chemotherapy, 2010, 54, 1055-1059.	3.2	23
133	The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	23
134	In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	23
135	Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opinion on Investigational Drugs, 2022, 31, 795-812.	4.1	23
136	In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. Journal of Antimicrobial Chemotherapy, 2006, 57, 288-293.	3.0	22
137	Pulmonary Fungal Infection Caused by Neoscytalidium dimidiatum. Journal of Clinical Microbiology, 2015, 53, 2381-2384.	3.9	22
138	In Vitro Activity of Essential Oils Against Gram-Positive and Gram-Negative Clinical Isolates, Including Carbapenem-Resistant Enterobacteriaceae. Open Forum Infectious Diseases, 2019, 6, ofz502.	0.9	22
139	Assessment of Serum (1â†'3)-Î²- <scp>d</scp> -Glucan Concentration as a Measure of Disease Burden in a Murine Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2008, 52, 1176-1178.	3.2	21
140	Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis. Clinical Microbiology and Infection, 2012, 18, E20-E23.	6.0	21
141	Pithomyces species (Montagnulaceae) from clinical specimens: identification and antifungal susceptibility profiles. Medical Mycology, 2014, 52, 748-757.	0.7	21
142	Nanopore Sequencing of the Fungal Intergenic Spacer Sequence as a Potential Rapid Diagnostic Assay. Journal of Clinical Microbiology, 2020, 58, .	3.9	21
143	Phaeohyphomycosis resulting in obstructive tracheitis in three green sea turtles Chelonia mydas stranded along the Florida coast. Diseases of Aquatic Organisms, 2015, 113, 257-262.	1.0	21
144	Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy, 2012, 67, 970-976.	3.0	20

#	Article	IF	Citations
145	A case of Exophiala oligosperma successfully treated with voriconazole. Medical Mycology Case Reports, 2013, 2, 144-147.	1.3	20
146	Paradoxical antifungal activity and structural observations in biofilms formed by echinocandin-resistant Candida albicans clinical isolates. Medical Mycology, 2014, 52, 131-139.	0.7	20
147	Efficacy of the Investigational Echinocandin ASP9726 in a Guinea Pig Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 2875-2881.	3.2	20
148	The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	20
149	Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model. Journal of Clinical Microbiology, 2016, 54, 960-966.	3.9	19
150	In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes. Mycoses, 2021, 64, 748-752.	4.0	19
151	Attenuation of Itraconazole Fungicidal Activity following Preexposure of Aspergillus fumigatus to Fluconazole. Antimicrobial Agents and Chemotherapy, 2003, 47, 3592-3597.	3.2	18
152	Dose tolerability of chronically inhaled voriconazole solution in rodents. International Journal of Pharmaceutics, 2009, 379, 25-31.	5.2	18
153	Clinical, Morphological, and Molecular Characterization of Penicillium canis sp. nov., Isolated from a Dog with Osteomyelitis. Journal of Clinical Microbiology, 2014, 52, 2447-2453.	3.9	18
154	Multilocus Phylogeny and Antifungal Susceptibility of Aspergillus Section Circumdati from Clinical Samples and Description of A. pseudosclerotiorum sp. nov. Journal of Clinical Microbiology, 2017, 55, 947-958.	3.9	18
155	Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	18
156	Species Distribution and Antifungal Susceptibilities of Aspergillus Section Fumigati Isolates in Clinical Samples from the United States. Journal of Clinical Microbiology, 2022, 60, e0028022.	3.9	18
157	Genomic Diversity across Candida auris Clinical Isolates Shapes Rapid Development of Antifungal Resistance In Vitro and In Vivo. MBio, 2022, 13, .	4.1	18
158	Enterobacter cloacaeVentriculitis Successfully Treated with Cefepime and Gentamicin: Case Report and Review of the Literature. Pharmacotherapy, 2003, 23, 537-542.	2.6	17
159	Morphological and Molecular Characterization of Exophiala polymorpha sp. nov. Isolated from Sporotrichoid Lymphocutaneous Lesions in a Patient with Myasthenia Gravis. Journal of Clinical Microbiology, 2015, 53, 2816-2822.	3.9	17
160	Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	17
161	Species of Aspergillus section Aspergillus from clinical samples in the United States. Medical Mycology, 2018, 56, 541-550.	0.7	17
162	Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	17

#	Article	IF	Citations
163	What's new in antifungals. Current Opinion in Infectious Diseases, 2015, 28, 539-545.	3.1	16
164	Acrophialophora, a Poorly Known Fungus with Clinical Significance. Journal of Clinical Microbiology, 2015, 53, 1549-1555.	3.9	16
165	New acremonium-like species in the Bionectriaceae and Plectosphaerellaceae. Mycological Progress, 2017, 16, 349-368.	1.4	16
166	Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. Pediatric Infectious Disease Journal, 2018, 37, 923-929.	2.0	16
167	Cryptic Aspergillus from clinical samples in the <scp>USA</scp> and description of a new species in section Flavipedes. Mycoses, 2018, 61, 814-825.	4.0	16
168	Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
169	Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial Membrane Potential. Journal of Fungi (Basel, Switzerland), 2021, 7, 130.	3.5	16
170	Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 115, 354-358.	0.4	15
171	Isolation and characterisation of the fungus <scp>S</scp>piromastix asexualis sp. nov. from discospondylitis in a <scp>G</scp>erman <scp>S</scp>hepherd dog, and review of <scp>S</scp>piromastix with the proposal of the new order <scp>S</scp>piromastixales (<scp>A</scp>scomycota). Mycoses, 2014, 57, 419-428.	4.0	15
172	Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract. Antimicrobial Agents and Chemotherapy, 2016, 60, 6703-6708.	3.2	15
173	PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS) Tj ETQq1 1 0.784314 rgBT 352-362.	0.6	15
174	The Black Yeasts: an Update on Species Identification and Diagnosis. Current Fungal Infection Reports, 2018, 12, 59-65.	2.6	14
175	Diversity of Veronaea botryosa from different hosts and evaluation of laboratory challenge models for phaeohyphomycosis in Acipenser transmontanus. Diseases of Aquatic Organisms, 2017, 125, 7-18.	1.0	14
176	From the Clinical Mycology Laboratory: New Species and Changes in Fungal Taxonomy and Nomenclature. Journal of Fungi (Basel, Switzerland), 2018, 4, 138.	3.5	13
177	Antifungal Resistance Testing and Implications for Management. Current Fungal Infection Reports, 2019, 13, 274-283.	2.6	13
178	Rasamsonia sp: An emerging infection amongst chronic granulomatous disease patients. A case of disseminated infection by a putatively novel Rasamsonia argillacea species complex involving the heart. Medical Mycology Case Reports, 2019, 24, 54-57.	1.3	13
179	Differential Thermotolerance Adaptation between Species of Coccidioides. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock	3.5	13
180	Multifocal Rhizopus microsporus lung infection following brush clearing. Medical Mycology Case Reports, 2014, 6, 14-17.	1.3	12

#	Article	IF	Citations
181	Antibacterials as Adjuncts to Incision and Drainage for Adults with Purulent Methicillin-Resistant Staphylococcus aureus (MRSA) Skin Infections. Drugs, 2012, 72, 339-351.	10.9	11
182	Schizophyllum radiatum, an Emerging Fungus from Human Respiratory Tract. Journal of Clinical Microbiology, 2016, 54, 2491-2497.	3.9	11
183	Effects of Treated versus Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species. Journal of Clinical Microbiology, 2016, 54, 734-738.	3.9	11
184	Multi-locus sequence typing provides epidemiological insights for diseased sharks infected with fungi belonging to the Fusarium solani species complex. Medical Mycology, 2018, 56, 591-601.	0.7	11
185	Pentamidine Is Active in a Neutropenic Murine Model of Acute Invasive Pulmonary Fusariosis. Antimicrobial Agents and Chemotherapy, 2006, 50, 294-297.	3.2	10
186	Invasive Fungal Infection Due to Triadelphia pulvinata in a Patient with Acute Myeloid Leukemia. Journal of Clinical Microbiology, 2013, 51, 3426-3429.	3.9	10
187	Paravertebral Mushroom: Identification of a Novel Species of Phellinus as a Human Pathogen in Chronic Granulomatous Disease. Journal of Clinical Microbiology, 2014, 52, 2726-2729.	3.9	10
188	APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection. Open Forum Infectious Diseases, 2017, 4, S475-S475.	0.9	10
189	Novel Paranannizziopsis species in a Wagler's viper (Tropidolaemus wagleri), tentacled snakes (Erpeton tentaculatum), and a rhinoceros snake (Rhynchophis boulengeri) in a zoological collection. Medical Mycology, 2019, 57, 825-832.	0.7	10
190	Novel Penicillium species causing disseminated disease in a Labrador Retriever dog. Medical Mycology, 2020, 58, 1053-1063.	0.7	10
191	Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. Infection and Drug Resistance, 2008, 1, 63-77.	2.7	10
192	Animal Models In Mycology: What Have We Learned Over The Past 30 Years. Current Fungal Infection Reports, 2013, 7, 68-78.	2.6	9
193	Influence of Serum and Albumin on Echinocandin In Vitro Potency and Pharmacodynamics. Current Fungal Infection Reports, 2013, 7, 89-95.	2.6	8
194	First Human Case of Fungal Keratitis Caused by a Putatively Novel Species of Lophotrichus. Journal of Clinical Microbiology, 2015, 53, 3063-3067.	3.9	8
195	Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	8
196	Disseminated Rasamsonia argillacea species complex infections in 8 dogs. Journal of Veterinary Internal Medicine, 2021, 35, 2232-2240.	1.6	8
197	A revision of malbranchea-like fungi from clinical specimens in the United States of America reveals unexpected novelty. IMA Fungus, 2021, 12, 25.	3.8	8
198	Diagnosis from Tissue: Histology and Identification. Journal of Fungi (Basel, Switzerland), 2022, 8, 505.	3.5	8

#	Article	IF	Citations
199	First Report of Westerdykella dispersa as a Cause of an Angioinvasive Fungal Infection in a Neutropenic Host. Journal of Clinical Microbiology, 2014, 52, 4407-4411.	3.9	7
200	Multilaboratory Evaluation of In Vitro Antifungal Susceptibility Testing of Dermatophytes for ME1111. Journal of Clinical Microbiology, 2016, 54, 662-665.	3.9	7
201	Fungal Keratitis Secondary to Trametes betulina: A Case Report and Review of Literature. Mycopathologia, 2017, 182, 755-759.	3.1	7
202	Variability of Hydroxy-Itraconazole in Relation to Itraconazole Bloodstream Concentrations. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	7
203	Comparison of MICs of Fluconazole and Flucytosine When Dissolved in Dimethyl Sulfoxide or Water. Journal of Clinical Microbiology, 2013, 51, 1955-1957.	3.9	6
204	Disseminated Conidiobolus incongruus in a dog: A case report and literature review. Medical Mycology Case Reports, 2015, 8, 24-28.	1.3	6
205	Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection. Diagnostic Microbiology and Infectious Disease, 2016, 84, 48-51.	1.8	6
206	New Species Spiromastigoides albida from a Lung Biopsy. Mycopathologia, 2017, 182, 967-978.	3.1	6
207	Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection. Drug Development and Industrial Pharmacy, 2017, 43, 264-274.	2.0	6
208	Antifungal Use in Veterinary Practice and Emergence of Resistance. , 2018, , 359-402.		6
209	Gastrointestinal pythiosis with concurrent presumptive gastrointestinal basidiobolomycosis in a Boxer dog. Veterinary Clinical Pathology, 2019, 48, 83-88.	0.7	6
210	Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	6
211	Rapid and Low-Cost Culture-Based Method for Diagnosis of Mucormycosis Using a Mouse Model. Frontiers in Microbiology, 2020, 11, 440.	3.5	6
212	Evaluation of Sex Differences in Murine Diabetic Ketoacidosis and Neutropenic Models of Invasive Mucormycosis. Journal of Fungi (Basel, Switzerland), 2021, 7, 313.	3.5	6
213	First report of human infection caused by Colletotrichum chlorophyti occurring in a post-corneal transplant patient with endophthalmitis. Medical Mycology Case Reports, 2021, 32, 73-76.	1.3	6
214	Prolyl endopeptidase activity in bronchoalveolar lavage fluid: a novel diagnostic biomarker in a guinea pig model of invasive pulmonary aspergillosis. Medical Mycology, 2013, 51, 592-602.	0.7	5
215	Multiple Brain Abscesses Caused by Trichosporon inkin in a Patient with X-Linked Chronic Granulomatous Disease (CGD) Successfully Treated with Antifungal Therapy. Journal of Clinical Immunology, 2017, 37, 519-523.	3.8	5
216	First Reported Case of Invasive Cutaneous Penicillium cluniae Infection in a Patient With Acute Myelogenous Leukemia: A Case Report and Literature Review. Open Forum Infectious Diseases, 2021, 8, ofab265.	0.9	5

#	Article	IF	Citations
217	Retrospective study of phaeohyphomycosis in aquariumâ€housed fish, with first descriptions of Exophiala lecaniiâ€corni and Neodevriesia cladophorae in fish. Journal of Fish Diseases, 2021, 44, 1563-1577.	1.9	5
218	Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. Infection and Drug Resistance, 0, , 63.	2.7	4
219	Fungal arthritis secondary to Colletotrichum gloeosporioides. JMM Case Reports, 2015, 2, .	1.3	4
220	Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata. International Journal of Antimicrobial Agents, 2016, 47, 286-288.	2.5	4
221	Development of aCandida glabratadominant nutritional transformation marker utilizing theAspergillus nidulansacetamidase gene (amdS). FEMS Yeast Research, 2016, 16, fow023.	2.3	4
222	Update on Therapeutic Drug Monitoring of Antifungals for the Prophylaxis and Treatment of Invasive Fungal Infections. Current Fungal Infection Reports, 2017, 11, 75-83.	2.6	4
223	Blastomyces helicus, an Emerging Dimorphic Fungal Pathogen Causing Fatal Pulmonary and Disseminated Disease in Humans and Animals in Western Canada and United States. Open Forum Infectious Diseases, 2017, 4, S83-S84.	0.9	4
224	Two new species ofGloniopsis(Hysteriales, Ascomycota) from clinical specimens: Morphological and molecular characterisation. Mycoses, 2019, 62, 1164-1173.	4.0	4
225	Genomic characterization of Parengyodontium americanum sp. nov. Fungal Genetics and Biology, 2020, 138, 103351.	2.1	4
226	Pseudocanariomyces americanus, gen. nov., sp. nov., A New Thielavia-Like Species in the Chaetomiaceae: Identification and Management of a Prosthetic Hip Infection. Mycopathologia, 2021, 186, 441-447.	3.1	4
227	Three new Curvularia species from clinical and environmental sources. MycoKeys, 2020, 68, 1-21.	1.9	4
228	Fusarium abutilonisandF. guadeloupense, two novel species in theFusarium buharicumclade supported by multilocus molecular phylogenetic analyses. Mycologia, 2022, 114, 682-696.	1.9	4
229	Loss ofin vitroresistance inCandida glabratafollowing discontinuation of fluconazole prophylaxis in a hematopoietic stem cell transplantation patient. Medical Mycology, 2010, 48, 557-560.	0.7	3
230	Invasive Microsporum canis causing rhinitis and stomatitis in a cat. Journal of Small Animal Practice, 2016, 57, 327-331.	1.2	3
231	Efficacy of echinocandins against murine infections by Diutina (Candida) rugosa. Diagnostic Microbiology and Infectious Disease, 2016, 86, 61-65.	1.8	3
232	Schwanniomyces etchellsii: an unusual cause of fungemia in a patient with cholecystitis. Diagnostic Microbiology and Infectious Disease, 2016, 84, 221-222.	1.8	3
233	A Novel Exophiala Species Associated With Disseminated Granulomatous Inflammation in a Captive Eastern Hellbender (Cryptobranchus alleganiensis alleganiensis). Frontiers in Veterinary Science, 2020, 7, 25.	2.2	3
234	Case Report: Successful Management of Conidiobolus Lamprauges Rhinitis in a Dog. Frontiers in Veterinary Science, 2021, 8, 633695.	2.2	3

#	Article	IF	Citations
235	Pharmacology, in vitro activity, and in vivo efficacy of new antifungal agents. Current Fungal Infection Reports, 2009, 3, 77-85.	2.6	2
236	Assessment of Aspergillus fumigatus in Guinea Pig Bronchoalveolar Lavages and Pulmonary Tissue by Culture and Realtime Polymerase Chain Reaction Studies. International Journal of Molecular Sciences, 2012, 13, 726-736.	4.1	2
237	Caspofungin for the Treatment of Immunocompromised and Severely Ill Children and Neonates with Invasive Fungal Infections. Clinical Medicine Insights Pediatrics, 2012, 6, CMPed.S8016.	1.4	2
238	Ustilago echinata: Infection in a Mixed Martial Artist Following an Open Fracture. Mycopathologia, 2016, 181, 311-314.	3.1	2
239	Lung Abscess Due to Aspergillus lentulus and Pseudomonas aeruginosa in a Patient With Granulomatosis With Polyangiitis. Infectious Diseases in Clinical Practice, 2018, 26, 100-105.	0.3	2
240	Pulmonary infection secondary to Blastobotrys raffinosifermentans in a cystic fibrosis patient: Review of the literature. Mycoses, 2021, 64, 616-623.	4.0	2
241	Moxifloxacin:. Journal of Public Health Pharmacy, 2003, 6, 1-26.	0.1	2
242	Trichosporonosis Presenting as an Exophytic Cutaneous Mass Lesion. Mycopathologia, 2020, 185, 705-708.	3.1	2
243	Polymeric Iron Chelator with Enhanced Iron Affinity as a Broad-Spectrum Antifungal Agent. ACS Applied Polymer Materials, 2021, 3, 6034-6039.	4.4	2
244	Reply to "Interlaboratory and Interstudy Reproducibility of a Novel Lateral-Flow Device: a Statistical Issue". Journal of Clinical Microbiology, 2013, 51, 1653-1653.	3.9	1
245	<scp>S</scp>tachybotrys eucylindrospora isolated from foreign material following a traumatic eye injury. Mycoses, 2014, 57, 437-441.	4.0	1
246	A Case of Phaeohyphomycosis Caused by Exophiala oligosperma in a Renal Transplant Patient Successfully Treated with Posaconazole. American Journal of Infectious Diseases, 2015, 11, 15-19.	0.2	1
247	In vitro Susceptibility Testing of Essential Oils against Gram-positive and Gram-negative Clinical Isolates, including Carbapenem-resistant Enterobacteriaceae (CRE). Open Forum Infectious Diseases, 2017, 4, S370-S370.	0.9	1
248	In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria. Open Forum Infectious Diseases, 2017, 4, S374-S374.	0.9	1
249	Invasive Rhinosinusitis Caused by Lasiodiplodia theobromae in an Allogeneic Hematopoietic Cell Transplant Recipient Case Report and Review of Literature. Mycopathologia, 2018, 183, 841-845.	3.1	1
250	Spiromastigoides asexualis: Phylogenetic Analysis and Evaluation as a Cause of False-Positive Blastomyces DNA Probe Test Results. Journal of Clinical Microbiology, 2020, 58, .	3.9	1
251	Implications of Evolving and Emerging Pharmacokinetic-Pharmacodynamic Research for Triazoles and Echinocandins. Current Fungal Infection Reports, 2020, 14, 258-267.	2.6	1
252	Fungal Drug Resistance: Azoles. , 2017, , 397-405.		1

#	Article	IF	Citations
253	Antifungal Therapy. , 0, , 1423-1432.		0
254	Using Antifungal Pharmacodynamics to Improve Patient Outcomes. Current Fungal Infection Reports, 2010, 4, 70-77.	2.6	0
255	Antifungal therapy. , 0, , 1344-1352.		0
256	Yeasts. Microbiology Spectrum, 2016, 4, .	3.0	0
257	Whatâ€™s Old is New: Recognition of New Fungal Pathogens in the Era of Phylogenetics and Changing Taxonomy and Implications for Medical Mycology. Fungal Biology, 2016, , 451-467.	0.6	0
258	2393. Evaluation of Antifungal Treatment in a Neutropenic Mouse Model of Scedosporiosis. Open Forum Infectious Diseases, 2018, 5, S713-S714.	0.9	0
259	Advanced Molecular Diagnosis of Fungal Infections. , 2018, , 403-421.		0
260	Probable case of Cephalotheca foveolata bloodstream infection. JMM Case Reports, 2015, 2, .	1.3	0
261	Yeasts. , 0, , 343-365.		0
262	Answer to December 2021 Photo Quiz. Journal of Clinical Microbiology, 2021, 59, e0289920.	3.9	0
263	Photo Quiz: You Get What You Get, and Sometimes Itâ€™s Tuberculate. Journal of Clinical Microbiology, 2021, 59, e0289720.	3.9	0